Originally published on Best Stocks Category: best stocks to buy now On Monday, HC Wainwright increased their price objective for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) from $35.00 to $50.00. As a direct consequence of this move, the stock reached a new 52-week high on Monday. The stock currently has a buy rating from HC Wainwright, which indicates that investors should consider purchasing it. During a trading session that saw the price of Amylyx Pharmaceuticals’ stock range from $37.25 to $37.24, 23739 shares were bought and sold by market participants. Before the market was shut down, a share of the company’s stock was trading for $36.28.Additional equity analysts have also published their research reports on the stocks they have monitored for the past few months. In a research note published by SVB Leerink on September 8, the company assigned an “outperform” rating to the shares of Amylyx Pharmaceuticals. In addition, the price target that the company had established for the company was increased to $50.00 from $31.00. In a research note published on September 9, Goldman Sachs Group raised their price objective on Amylyx Pharmaceuticals from $22.00 to $40.00 and gave the company a “neutral” rating in a research note. The note was distributed to the public on Friday. Citigroup gave the company a “buy” rating in a research report published on Monday, October 3. It raised its price objective on Amylyx Pharmaceuticals from $48.00 to $50.00 in a research report published on Monday, October 3. The report was released in conjunction with the company’s quarterly earnings report. The company’s stock was considered when both of these modifications were made. The vast majority of financial analysts have suggested that investors purchase the stock, and only one of them has suggested that investors keep the same number of holdings they already have. According to information from Bloomberg.com, the current consensus recommendation for Amylyx Pharmaceuticals is “Moderate Buy,” and the average price goal for the company is $47.50.On Thursday, September 8, Global Investors L.P. Viking, the company that holds the most shares in Amylyx Pharmaceuticals, sold 700,000 of those shares. This brings us to another piece of news about the recently released company. During the sale, purchasers paid an average price of $29.37 for each share, resulting in a total amount of $20,559,000.00 for all of the shares. After the completion of the sale, the company insider now directly owns 2,075,470 shares of the company. Based on the current stock price, these shares are worth $60,956,553.90. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC regarding the transaction, which is currently available. The company’s insiders hold a stake equivalent to 12.70% of the total stock in the company.The company’s simple moving average over the past 50 days is $28.54, while the company’s simple moving average over the past 200 days is $20.15.On Thursday, August 11, the most recent quarterly earnings report for Amylyx Pharmaceuticals was released. This report, which can be found under the ticker symbol “NASDAQ: AMLX,” can be found online. The company reported that it had earnings of $0.93 per share for the quarter, which was $0.03 less than the consensus estimate ($0.92) among financial analysts. Analysts who do equity research predict that Amylyx Pharmaceuticals, Inc. will have earnings per share (EPS) of -3.6 for the current fiscal year.Amyotrophic lateral sclerosis (ALS) and other neurological conditions are among those for which Amylyx Pharmaceuticals, Inc., a biopharmaceutical company currently in clinical testing, is researching and developing potential remedies. The company is currently located in the United States. In the treatment of amyotrophic lateral sclerosis (ALS), AMX0035 is an apoptotic inhibitor that acts on both the UPR and the Bax proteins. Taurursodiol and sodium phenylbutyrate are the two components that go into its production. The inhibitor is one of the potential products that the company is working on developing.